<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Menopausal hormone therapy in the prevention and treatment of osteoporosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Menopausal hormone therapy in the prevention and treatment of osteoporosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Menopausal hormone therapy in the prevention and treatment of osteoporosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold N Rosen, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William F Crowley, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Women have menopause at a mean age of 51 years. The resulting lack of estrogen is associated with rapid bone loss due to increased bone resorption and often consequent osteoporosis. (See  <a class="medical medical_review" href="/d/html/2044.html" rel="external">"Pathogenesis of osteoporosis"</a>.)</p><p>Although menopausal hormone therapy (MHT) is not a first-line option for the prevention of osteoporosis, because of concerns of adverse effects, women who are already taking estrogen for menopausal symptom relief have the additional benefit of skeletal protection. This topic will review the efficacy of estrogen therapy on the prevention and treatment of postmenopausal bone loss. The approach to osteoporosis management, the benefits and risks of estrogen therapy, and our current recommendations for estrogen use are discussed separately. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy"</a> and  <a class="medical medical_review" href="/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks"</a>.)</p><p class="headingAnchor" id="H1165667596"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>In the past, menopausal hormone therapy (MHT) was often prescribed for prevention of osteoporosis and coronary heart disease (CHD), based upon epidemiologic data demonstrating a protective effect of estrogen on the heart and bone. However, data from the Women's Health Initiative (WHI), which evaluated oral <a class="drug drug_general" data-topicid="9424" href="/d/drug information/9424.html" rel="external">conjugated equine estrogen</a> (0.625 mg/day) with or without <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (2.5 mg/day) in postmenopausal women (mean age 63 to 64 years at beginning of study and not selected on the basis of low bone mineral density [BMD]), showed a number of adverse outcomes, including an excess risk of CHD, stroke, venous thromboembolism (VTE), and breast cancer [<a href="#rid1">1,2</a>]. In light of the WHI data and the efficacy of other osteoporosis drugs, MHT (in particular the regimens used in the WHI) are no longer used for the prevention of chronic conditions. (See  <a class="medical medical_review" href="/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks", section on 'Overview'</a>.)</p><p>The increased risk of adverse events in the WHI was largely due to the older age of the study population. Follow-up analyses from the WHI and other studies have since demonstrated that the benefits of MHT outweigh the risks for women who are in their 50s, or less than 10 years from menopause. MHT is currently used in this population for management of menopausal symptoms, most importantly, hot flashes. Current regimens of MHT most often include 17-beta <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> and micronized <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a>, preparations that have a number of advantages over those used in the WHI. The duration of therapy is typically up to four to five years, although some women with persistent symptoms are treated for longer. (See  <a class="medical medical_review" href="/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks", section on 'Estimates of risk in women 50 to 59 years'</a> and  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy"</a>.)</p><p>Women who seek MHT for menopausal symptoms in their late 40s or early 50s will have the additional benefit of a reduced risk of bone loss and fracture [<a href="#rid3">3,4</a>]. In such women, a separate first-line drug for prevention or treatment of osteoporosis is usually not required with estrogen (<a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a>) doses equivalent to or higher than 25 mcg/day of transdermal or 0.5 mg/day oral. Lower doses of transdermal estradiol (14 mcg) have also been shown to have skeletal benefits. With this ultra-low dose of transdermal estrogen, bone density should be monitored in women at high risk for osteoporosis and fracture as another agent (eg, a bisphosphonate) may be needed. (See  <a class="medical medical_review" href="/d/html/7446.html" rel="external">"Preparations for menopausal hormone therapy"</a> and <a class="local">'Prevention of osteoporosis'</a> below.)</p><p>Women who desire osteoporosis preventive therapy, but do not need MHT for menopausal symptoms, are prescribed other antiresorptive drugs (eg, bisphosphonates, <a class="drug drug_general" data-topicid="9593" href="/d/drug information/9593.html" rel="external">raloxifene</a>). (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EFFICACY OF ESTROGEN THERAPY</span></p><p class="headingAnchor" id="H3"><span class="h2">Prevention of osteoporosis</span><span class="headingEndMark"> — </span>Numerous randomized, placebo-controlled studies, including the Women's Health Initiative (WHI) and the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial [<a href="#rid5">5</a>], have established that the postmenopausal decrease in bone density is attenuated by estrogen, resulting in a lower risk of fracture [<a href="#rid1">1,5-10</a>]. Nevertheless, most experts no longer recommend estrogen as first-line therapy for prevention of osteoporosis, given the results of the WHI. For women using MHT for relief of symptomatic hot flashes, however, a separate first-line drug for prevention of osteoporosis is usually not required. (See <a class="local">'General principles'</a> above and  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of bone loss</strong> – Estrogen therapy prevents bone loss. In one study, as an example, 43 postmenopausal women were randomly assigned to treatment with percutaneous 17-beta <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a>, calcium, or placebo for two years and followed with sequential measurements of bone density by dual photon absorptiometry [<a href="#rid6">6</a>]. Treatment with estrogen prevented bone loss in the forearm and whole body and increased bone density of the spine; it was significantly more effective than calcium or placebo.</p><p></p><p class="bulletIndent1">The results were similar in a placebo-controlled study of 120 postmenopausal women with <strong>low bone density</strong> who were randomly assigned to treatment with exercise plus either placebo, calcium, or estrogen (1.25 mg estropipate); these women were followed with sequential measurements of forearm bone density [<a href="#rid7">7</a>]. Although calcium supplementation reduced bone loss at the distal forearm compared with placebo, treatment with estrogen was much more effective in preventing loss of bone density in the proximal, middle, and distal forearm than were the other treatments (<a class="graphic graphic_figure graphicRef62388" href="/d/graphic/62388.html" rel="external">figure 1</a>). </p><p></p><p class="bulletIndent1">Among postmenopausal women not taking estrogen, those with low (but detectable) serum <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> concentrations have higher bone density than those with undetectable concentrations [<a href="#rid11">11</a>]. Based upon this observation, lower doses of estrogen have been explored as a strategy to prevent bone loss while minimizing side effects and breast cancer risk [<a href="#rid12">12-14</a>]. Almost all studies suggest that lower doses of estrogen also prevent bone loss, particularly when adequate vitamin D and calcium intake are provided. (See  <a class="medical medical_review" href="/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one study, 406 recently postmenopausal women were randomly assigned to unopposed esterified estrogen at one of three doses (0.3, 0.625, and 1.25 mg/day) or placebo [<a href="#rid15">15</a>]. All three doses prevented bone loss, while endometrial hyperplasia occurred only at the two higher doses (<a class="graphic graphic_figure graphicRef50951" href="/d/graphic/50951.html" rel="external">figure 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is evidence that even ultra-low doses of estrogen (roughly equivalent to oral <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> 0.25 mg/day or conjugated estrogens 0.15 mg/day) provide some protection against bone loss. A 0.014 mg/day transdermal estradiol patch and oral estradiol (0.25 mg/day) both appear to prevent bone loss [<a href="#rid16">16-18</a>]. (See  <a class="medical medical_review" href="/d/html/7446.html" rel="external">"Preparations for menopausal hormone therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of fracture</strong> – The WHI provides the best evidence that estrogen reduces fracture risk. In the WHI trial, both unopposed estrogen and combined estrogen-progestin treatment reduced fracture risk. In this study, hip fracture was a secondary outcome, and women were not selected based upon osteoporosis history or risk factors. While bone mineral density (BMD) was not measured, estrogen-progestin therapy was associated with significant reductions in [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hip fracture (10 versus 15 per 10,000 person-years, hazard ratio [HR] 0.66, unadjusted 95% CI 0.45-0.98) (<a class="graphic graphic_figure graphicRef55425" href="/d/graphic/55425.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vertebral (0.5 versus 0.7 percent, HR 0.66, unadjusted 95% CI 0.44-0.98) and other osteoporotic fractures (6.8 versus 8.6 percent, HR 0.77, 95% CI 0.69-0.86, respectively).</p><p></p><p class="bulletIndent1">Similar risk reductions were seen in the unopposed estrogen arm of the WHI trial for hip fracture (HR 0.61, 95% CI 0.41-0.91) and vertebral fracture (HR 0.62, 95% CI 0.42-0.93) [<a href="#rid2">2</a>]. Other results of the trial are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks"</a>.)</p><p></p><p class="bulletIndent1">A limitation of the WHI is that BMD was not a criterion for randomization. Thus, the results are not conclusive, because the bone density in the two groups may have been different at baseline. </p><p></p><p class="bulletIndent1">All types of postmenopausal hormone therapy appear to confer benefit. In a prospective, cohort study of over one million women (the Million Women Study), current users of postmenopausal hormone therapy had a significantly lower risk of any fracture than nonusers (relative risk [RR] 0.62, 95% CI 0.58-0.66) [<a href="#rid19">19</a>]. The protective effect was seen for all types of postmenopausal hormone therapy (unopposed estrogen, combined estrogen-progestin, different estrogen and progestin formulations, different routes of administration [oral versus transdermal], and different patterns of administration [cyclic versus continuous]).</p><p></p><p class="bulletIndent1">Concomitant administration of a progestin to prevent endometrial hyperplasia does not interfere with the beneficial effect of estrogen on bone, whether given as cyclic or continuous therapy [<a href="#rid5">5,20</a>]. (See  <a class="medical medical_review" href="/d/html/7446.html" rel="external">"Preparations for menopausal hormone therapy"</a> and  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Current versus past therapy</strong> – The maximum protection of bone mass appears to occur when estrogen therapy is begun soon after menopause and then continued indefinitely (although this is no longer the way MHT is prescribed). As an example, cross-sectional data from the Rancho Bernardo study found that women who had taken estrogen in the past and then discontinued it had slightly higher bone density than women who had never taken estrogen, but their bone density was substantially lower than women currently taking estrogen (<a class="graphic graphic_figure graphicRef51367" href="/d/graphic/51367.html" rel="external">figure 4</a>) [<a href="#rid21">21</a>]. Other studies have noted similar findings: higher bone mass in women currently taking estrogen [<a href="#rid22">22</a>] and in those treated long term [<a href="#rid23">23-25</a>].</p><p></p><p class="bulletIndent1">The limited efficacy of past estrogen therapy may reflect "catch-up" bone loss, although data have been conflicting [<a href="#rid26">26-28</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One study in 43 postmenopausal women found that those not treated with estrogen after oophorectomy initially lost bone at a rate of 2.6 percent per year, which later fell to 0.8 percent per year (<a class="graphic graphic_figure graphicRef51608" href="/d/graphic/51608.html" rel="external">figure 5</a>) [<a href="#rid26">26</a>]. Those treated with estrogen for four years lost no bone, but after it was discontinued, they lost bone at a rate of 2.5 percent per year for the next four years. There was no significant difference in bone loss between the two groups at eight years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one study of postmenopausal women posthysterectomy, the women were randomly assigned to receive <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a>, estrogen, combination therapy, or placebo for two years, followed by further randomization to continued drug therapy or placebo in year 3. Bone density decreased in year 3 after stopping estrogen (-4.5, 1.8, and 2.4 percent in the spine, total hip, and femoral neck, respectively) but not after stopping alendronate or combined alendronate-estrogen treatment [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In contrast, in the much larger PEPI trial, postmenopausal women who discontinued estrogen did not lose bone at an unusually fast rate. In this study of 495 women who had measurements of BMD for an average of three years during and four years after the trial, annual rates of BMD loss in the women who took estrogen and then stopped it and those who never took estrogen were the same (approximately 1 percent per year) [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1">Thus, data on accelerated bone loss after stopping estrogen therapy are inconsistent. Even if there is accelerated bone loss after stopping estrogen, it is unlikely to cause loss of all of the BMD preserved on treatment, as most studies show that postmenopausal women who have taken estrogen in the past have higher BMD than those who have never taken it [<a href="#rid30">30</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Treatment of established osteoporosis</span><span class="headingEndMark"> — </span>Estrogen is not a first-line treatment of established osteoporosis in postmenopausal women due to the availability of more potent agents. In postmenopausal women taking estrogen therapy to treat menopausal symptoms, estrogen may be sufficient to treat osteoporosis. Bone density should be monitored in women at high risk for fracture as another agent (eg, a bisphosphonate) may be needed. (See <a class="local">'General principles'</a> above and  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Choice of initial therapy'</a>.)</p><p>Although estrogen therapy is US Food and Drug Administration (FDA) approved for prevention but not treatment of osteoporosis, data suggest that estrogen is effective in postmenopausal women with established osteoporosis and vertebral fractures. In one study, 75 such women were randomly assigned to treatment with transdermal <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> (0.1 mg) or placebo; calcium supplements were given to both groups [<a href="#rid31">31</a>]. Estrogen was associated with an increase in bone density in the spine and proximal femur and no change in bone density in the mid-radius. It also lowered the risk of vertebral fractures by more than 50 percent (23 versus 58 fractures per 100 patient-years).</p><p>Estrogen appears to be effective even when started after age 75 years, although this is <strong>not </strong>recommended. As an example, in 67 frail older women (over age 75 years), administration of estrogen for nine months increased bone density at the lumbar spine and hip as compared with placebo (4.3 versus 0.4 percent in the spine; 1.7 versus -0.1 percent in the hip) [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Estrogen versus bisphosphonate therapy</span><span class="headingEndMark"> — </span>Estrogen with <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> was similar in efficacy to <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> therapy for preventing bone loss in one study of women ages 45 to 59 years (<a class="graphic graphic_figure graphicRef65252" href="/d/graphic/65252.html" rel="external">figure 6</a>) [<a href="#rid33">33</a>], and in a study of older women [<a href="#rid34">34</a>], while alendronate was superior to combination hormone replacement in one study of older postmenopausal women (ages 65 to 90 years) [<a href="#rid35">35</a>]. Bone loss may be greater after stopping estrogen than alendronate [<a href="#rid29">29</a>].</p><p>Combination therapy (estrogen plus bisphosphonate) has been more effective in raising BMD than either agent alone in some [<a href="#rid35">35,36</a>], but not all [<a href="#rid34">34</a>], studies. We prefer not to use combination therapy for preventing bone loss as the additional BMD benefits are small and there is no proven additional fracture benefit. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">PROGESTIN THERAPY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">Progesterone</a> inhibits bone resorption and has some beneficial effects on bone density when given to estrogen-deficient women [<a href="#rid37">37,38</a>]. However, the beneficial effect of progesterone on bone mineral density (BMD) is small compared with that of estrogen.</p><p>As an example, in one study in postmenopausal women who took either conjugated estrogens (0.625 mg per day), high doses of medroxyprogesterone (20 mg per day), or placebo, spine BMD fell 7 percent in those treated with placebo but fell only 5 percent in women receiving medroxyprogesterone [<a href="#rid20">20</a>]. On the other hand, BMD increased by 2 percent in women taking conjugated estrogens.</p><p>Combined estrogen-progestin therapy does not increase the efficacy of estrogen alone on bone [<a href="#rid5">5,9</a>]. This issue was best addressed in the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial in which 875 women were randomly assigned to placebo or one of four treatment arms consisting of conjugated estrogens (0.625 mg/day) alone or with cyclic or continuous medroxyprogesterone or cyclic micronized <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> (200 mg/day for 12 days per month) [<a href="#rid5">5</a>]. At three years, bone density increased similarly in all treatment groups by 3.5 to 5.0 percent at the spine and 1.7 percent at the hip; in contrast, bone density fell at these sites by 1.8 and 1.7 percent, respectively, in the placebo group.</p><p class="headingAnchor" id="H4100650820"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/105492.html" rel="external">"Society guideline links: Osteoporosis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/113098.html" rel="external">"Society guideline links: Menopause"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Although menopausal hormone therapy (MHT) is an option for the prevention of osteoporosis in perimenopausal women, we no longer consider it a first-line therapy, since data from the Women's Health Initiative (WHI) suggest that in older menopausal women, estrogen-progestin therapy reduces fracture risk at a cost of increases in the incidence of breast cancer, coronary heart disease (CHD), stroke, and venous thromboembolism (VTE), or in the case of unopposed estrogen, an increase in stroke and thromboembolism risk (but not CHD or breast cancer). (See <a class="local">'General principles'</a> above and  <a class="medical medical_review" href="/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of osteoporosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Women taking MHT for menopausal symptoms</strong> – Although MHT is no longer prescribed for chronic conditions, it is indicated for the treatment of menopausal hot flashes in younger menopausal women. Women who seek MHT for menopausal symptoms in their late 40s or early 50s will have the additional benefit of a reduced risk of bone loss and fracture. (See <a class="local">'General principles'</a> above and <a class="local">'Prevention of osteoporosis'</a> above.)</p><p></p><p class="bulletIndent2">In such women, a separate first-line drug for prevention of osteoporosis is usually not required with estrogen (<a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a>) doses equal to or higher than 25 mcg/day of transdermal or 0.5 mg/day oral. Lower doses of transdermal estradiol (14 mcg) have also been shown to have skeletal benefits. We monitor bone density in women at high risk for osteoporosis and fracture who are taking ultra-low-dose transdermal estrogen as another agent (eg, a bisphosphonate) may be needed. (See <a class="local">'General principles'</a> above and <a class="local">'Prevention of osteoporosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Women not taking MHT for menopausal symptoms</strong> – Women who desire osteoporosis preventive therapy, but do not need MHT for menopausal symptoms, are prescribed other antiresorptive drugs (eg, bisphosphonates, <a class="drug drug_general" data-topicid="9593" href="/d/drug information/9593.html" rel="external">raloxifene</a>). (See <a class="local">'General principles'</a> above and  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of established osteoporosis</strong> – Estrogen is <strong>not</strong> a first-line approach for the treatment of established osteoporosis in postmenopausal women due to availability of more potent agents. In postmenopausal women taking estrogen to treat persistent menopausal symptoms, estrogen may be sufficient to treat osteoporosis. Bone density should be monitored in women at high risk for fracture as another agent (eg, a bisphosphonate) may be needed. (See <a class="local">'General principles'</a> above and <a class="local">'Treatment of established osteoporosis'</a> above and  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Choice of initial therapy'</a>.)</p><p></p><p class="headingAnchor" id="H2665342737"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Marc K Drezner, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.</a></li><li><a class="nounderline abstract_t">Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701.</a></li><li><a class="nounderline abstract_t">Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013; 310:1353.</a></li><li><a class="nounderline abstract_t">Rozenberg S, Al-Daghri N, Aubertin-Leheudre M, et al. Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? Osteoporos Int 2020; 31:2271.</a></li><li><a class="nounderline abstract_t">Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996; 276:1389.</a></li><li><a class="nounderline abstract_t">Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. N Engl J Med 1987; 316:173.</a></li><li><a class="nounderline abstract_t">Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 1991; 325:1189.</a></li><li><a class="nounderline abstract_t">Aloia JF, Vaswani A, Yeh JK, et al. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med 1994; 120:97.</a></li><li><a class="nounderline abstract_t">Munk-Jensen N, Pors Nielsen S, Obel EB, Bonne Eriksen P. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study. Br Med J (Clin Res Ed) 1988; 296:1150.</a></li><li><a class="nounderline abstract_t">Field CS, Ory SJ, Wahner HW, et al. Preventive effects of transdermal 17 beta-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol 1993; 168:114.</a></li><li><a class="nounderline abstract_t">Ettinger B, Pressman A, Sklarin P, et al. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab 1998; 83:2239.</a></li><li><a class="nounderline abstract_t">Ettinger B, Genant HK, Steiger P, Madvig P. Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992; 166:479.</a></li><li><a class="nounderline abstract_t">Stevenson JC, Cust MP, Gangar KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 336:265.</a></li><li><a class="nounderline abstract_t">Speroff L, Rowan J, Symons J, et al. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA 1996; 276:1397.</a></li><li><a class="nounderline abstract_t">Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med 1997; 157:2609.</a></li><li><a class="nounderline abstract_t">Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004; 104:443.</a></li><li><a class="nounderline abstract_t">Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003; 290:1042.</a></li><li><a class="nounderline abstract_t">Huang AJ, Ettinger B, Vittinghoff E, et al. Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women. J Bone Miner Res 2007; 22:1791.</a></li><li><a class="nounderline abstract_t">Banks E, Beral V, Reeves G, et al. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 2004; 291:2212.</a></li><li><a class="nounderline abstract_t">Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 1991; 90:171.</a></li><li><a class="nounderline abstract_t">Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA 1997; 277:543.</a></li><li><a class="nounderline abstract_t">Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995; 122:9.</a></li><li><a class="nounderline abstract_t">Cauley JA, Zmuda JM, Ensrud KE, et al. Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab 2001; 86:5700.</a></li><li><a class="nounderline abstract_t">Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329:1141.</a></li><li><a class="nounderline abstract_t">Michaëlsson K, Baron JA, Farahmand BY, et al. Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ 1998; 316:1858.</a></li><li><a class="nounderline abstract_t">Lindsay R, Hart DM, MacLean A, et al. Bone response to termination of oestrogen treatment. Lancet 1978; 1:1325.</a></li><li><a class="nounderline abstract_t">Christiansen C, Christensen MS, Transbøl I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981; 1:459.</a></li><li><a class="nounderline abstract_t">Greendale GA, Espeland M, Slone S, et al. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Intern Med 2002; 162:665.</a></li><li><a class="nounderline abstract_t">Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137:875.</a></li><li><a class="nounderline abstract_t">Papadakis G, Hans D, Gonzalez-Rodriguez E, et al. The Benefit of Menopausal Hormone Therapy on Bone Density and Microarchitecture Persists After its Withdrawal. J Clin Endocrinol Metab 2016; 101:5004.</a></li><li><a class="nounderline abstract_t">Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117:1.</a></li><li><a class="nounderline abstract_t">Villareal DT, Binder EF, Williams DB, et al. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. JAMA 2001; 286:815.</a></li><li><a class="nounderline abstract_t">Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999; 131:935.</a></li><li><a class="nounderline abstract_t">Eviö S, Tiitinen A, Laitinen K, et al. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. J Clin Endocrinol Metab 2004; 89:626.</a></li><li><a class="nounderline abstract_t">Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003; 289:2525.</a></li><li><a class="nounderline abstract_t">Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998; 104:219.</a></li><li><a class="nounderline abstract_t">Horowitz M, Wishart J, Need AG, et al. Treatment of postmenopausal hyperparathyroidism with norethindrone. Effects on biochemistry and forearm mineral density. Arch Intern Med 1987; 147:681.</a></li><li><a class="nounderline abstract_t">Abdalla HI, Hart DM, Lindsay R, et al. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol 1985; 66:789.</a></li></ol></div><div id="topicVersionRevision">Topic 7428 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12117397" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15082697" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24084921" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32642851" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8892713" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3540668" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1922205" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8256988" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3132244" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8420311" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Preventive effects of transdermal 17 beta-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9661589" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1536215" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1973969" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8892714" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9531230" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15339752" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12941676" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620054" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15138243" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1847582" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9032160" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7985914" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739424" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Timing of estrogen replacement therapy for optimal osteoporosis prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8377776" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The effect of postmenopausal estrogen therapy on bone density in elderly women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9632404" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/78095" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bone response to termination of oestrogen treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6110089" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11911720" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12458987" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27854548" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The Benefit of Menopausal Hormone Therapy on Bone Density and Microarchitecture Persists After its Withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1534476" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Treatment of postmenopausal osteoporosis with transdermal estrogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11497535" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10610644" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764773" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12759324" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9552083" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3827457" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Treatment of postmenopausal hyperparathyroidism with norethindrone. Effects on biochemistry and forearm mineral density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4069480" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prevention of bone mineral loss in postmenopausal women by norethisterone.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
